Vitamin C supplementation in the critically ill: A systematic review and meta-analysis

Michael Zhang1 and David F Jativa2

Abstract

Background: Low plasma levels of vitamin C are associated with adverse outcomes, including increased mortality, in critically ill patients. Several trials have suggested that the administration of intravenous vitamin C in this setting may have beneficial effects, such as reducing the incidence of organ failure and improving survival. However, these studies have generally involved combination therapies consisting of vitamin C along with other antioxidants, confounding the effects of vitamin C alone. The primary objective of this meta-analysis is to investigate the effects of isolated intravenous supplementation of vitamin C in adults with critical illness.

Methods: A database search was conducted for studies on the use of intravenous vitamin C in adult patients with critical illness. The primary outcome assessed was mortality at the longest follow-up time available. Secondary outcomes were the duration of mechanical ventilation, duration of vasopressor support, fluid requirements, and urine output in the first 24 h of intensive care unit admission.

Results: Five studies (four randomized controlled trials and one retrospective review) enrolling a total of 142 patients were included in this meta-analysis. Compared with controls, the administration of intravenous vitamin C was associated with a decreased need for vasopressor support (standardized mean difference −0.71; 95% confidence interval (−1.16 to −0.26); \( p = 0.002 \)) and decreased duration of mechanical ventilation (standardized mean difference −0.5; 95% confidence interval (−0.93 to −0.06); \( p = 0.03 \)), but no difference was found in mortality (odds ratio 0.76; 95% confidence interval (0.27 to 2.16); \( p = 0.6 \)). Trends were also noted toward decreased fluid requirements and increased urine output. No adverse effects were reported.

Conclusion: The administration of intravenous vitamin C may lead to vasopressor sparing effects and a reduced need for mechanical ventilation in the critically ill, without affecting overall mortality. However, these results should be interpreted in light of the limitations of the primary literature and should serve as a preview of upcoming trials in this area.

Keywords

Critical care, emergency medicine, respiratory medicine, sepsis, nutrition, respiratory distress, shock, vitamin C, acute respiratory distress syndrome

Date received: 29 May 2018; accepted: 21 September 2018

Introduction

Vitamin C is a water-soluble vitamin with a variety of antioxidant,1 anti-inflammatory,2 and microvascular3 effects. Widely used in over-the-counter formulations for the common cold and general well-being,4 in recent years, there has been an expanding role for the use of vitamin C in the hospital setting. Although the overall prevalence of hypovitaminosis C is around 7.1% in the general population,5 up to 47.3% of undifferentiated hospitalized patients are deficient in vitamin C.6

Vitamin C levels are known to be decreased in critical illness7–10 and are associated with severity of illness.7,11 Although vitamin C requirements are greater in this population due to increased oxidative stress,12 levels may be restored to normal,8,13 or even brought to supra-normal,14 with parenteral supplementation.

1Department of Medicine, VA Medical Center, Cleveland, OH, USA
2Department of Medicine, Aventura Hospital & Medical Center, Aventura, FL, USA

Corresponding author:
Michael Zhang, Department of Medicine, VA Medical Center, 10701 East Blvd, Cleveland, OH 44106, USA.
Email: maz19@case.edu
Supplemental vitamin C has shown promise in both animal models of sepsis and human trials in the intensive care unit (ICU) setting. Although a simple vitamin, a variety of biological mechanisms have been postulated to account for the beneficial actions of vitamin C in the context of sepsis and organ failure. These include the prevention and restoration of micro-circulatory flow impairment due to reactive oxygen species, the preservation of vascular responsiveness to vasoconstrictors, the preservation of endothelial barrier function, and augmentation of anti-bacterial defense, leading to an overall mitigation of organ injury and dysfunction in critically ill patients.

However, the largest studies with the most promising results have investigated vitamin C as part of combination (“cocktail”) therapies administered together with vitamin E or thiamine plus hydrocortisone. The last study is particularly impressive, demonstrating a substantial (8.5% versus 40.4%) reduction in mortality as well as decreased Sequential Organ Failure Assessment (SOFA) scores and length of vasopressor support compared to controls, but it is unclear which, if any, of the three constituents was responsible for these effects, obscuring the true effect of vitamin C. Furthermore, questions have been raised regarding the methodology of this study with respect to its small sample size, lack of randomization, and retrospective design.

Few studies have focused specifically on the benefits of isolated administration of vitamin C in critically ill patients. Generally, these studies have been small and have yielded few conclusive results, and a comprehensive synthesis of the data has not been conducted heretofore. Hence, we aim in this review to provide a comprehensive meta-analysis of all studies involving isolated vitamin C administration in critically ill patients and to examine the effects upon overall mortality in addition to common clinical parameters in this setting, such as vasopressor requirements, the duration of mechanical ventilation, and resuscitation fluid requirements.

**Methods and materials**

**Data sources**

This study was conducted and prepared per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We aimed to collect all studies which assessed the use of intravenous vitamin C in adult patients with critical illness. The following databases were searched for English language articles published from inception to September 2017: MEDLINE, Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews, and Elsevier. The following keywords were used along with MeSH terms: “vitamin C” or “ascorbic” or “ascorbate” and “sepsis” or “septic” or “shock” or “respiratory distress” or “ARDS” or “lung injury” or “critical” or “critically” or “intensive” or “ICU” or “trauma” or “burn.” All search terms were exploded and no restrictions or limitations were placed in our search strategy.

**Study selection criteria**

We included trials with the following characteristics:

1. Type of studies: prospective and retrospective clinical trials;
2. Population: adult ICU patients;
3. Intervention: intravenous vitamin C supplementation versus placebo or no intervention, with no minimum dose.
4. Study outcome: The primary outcome examined was cause mortality in the longest duration provided by the studies. Secondary outcomes were the duration of mechanical ventilation, duration of vasopressor support, fluid requirements, and urine output in the first 24 h of ICU admission.

Trials with these characteristics were excluded:

1. They were not published as original studies;
2. They were not published in English;
3. They did not use adult patients;
4. They did not use vitamin C alone without other interventions;
5. Full-text articles not available;
6. Lack of data on mortality;
7. Case reports;
8. Animal studies.

**Data extraction**

Data from included studies were extracted independently by both authors, and discrepancies were resolved through discussion until consensus was reached. The primary outcome was all cause mortality in the longest duration provided by the studies. Secondary outcomes were the duration of mechanical ventilation, duration of vasopressor support, and fluid requirements and urine output in the first 24 h of ICU admission. When appropriate, standard deviations were estimated using previously described methods. For standardized mean difference (SMD) analysis, scales of differing directionality were standardized when necessary with multiplication by −1.

**Risk of bias**

We used the Cochrane Collaboration’s tool for assessing risk of bias to evaluate the quality of the included randomized controlled trials. Domains assessed were random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. The remaining observational study was similarly assessed with the ROBINS-I tool. Studies were considered to be low risk only if every domain was individually adjudicated as such;
otherwise, any domain rated as unclear or high risk brought the overall risk to that respective stratification.

Statistical analysis

Data were analyzed by Review Manager 5.3 (The Nordic Cochrane Center, Rigshospitalet, Copenhagen, Denmark). Results are presented with forest plots using odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous data and SMD with 95% CI for continuous data. The statistical heterogeneity among the studies was calculated and assessed with the I² test based on previously recommended stratifications (low, moderate, and high to I² values of 25%, 50%, and 75%, respectively).39 A Mantel–Haenszel (MH) method was used for the dichotomous primary outcome of mortality. For all continuous outcomes, inverse variance methods were used. In addition, the random effects model of DerSimonian and Laird was used if heterogeneity was observed; otherwise, a fixed effects model was used. The p value of <0.05 was considered statistically significant. Tests for publication bias, such as the funnel plot and Egger’s linear regression, were not utilized due to the low number of included studies.

Results

Study selection

The literature search strategy outlined above returned 3961 citations (Figure 1). After duplicates were expunged, 3478 articles were scanned by titles and abstracts, and 3425 non-relevant studies were removed. The remaining 53 articles were assessed for eligibility. Notable exclusions were due to pre- or perioperative administration for scheduled cardiac (n = 14),40–53 gastrointestinal (n = 1),54 vascular (n = 1),55 or gynecologic (n = 1)56...
surgery, administration as part of combination therapy with other agents (n = 27),27–31,57–78 or case reports (n = 3).79–81 Many of the above were also excluded due to enteral administration. One study was excluded because the investigators sought to normalize plasma ascorbic acid by administering varying doses depending on baseline levels; this study also did not report clinical outcomes.82 Finally, five studies (Table 1) were included in this meta-analysis.22–26

**Study characteristics and quality**

These five studies (four RCTs and one retrospective review) enrolled a total of 142 patients, of whom 76 received intravenous vitamin C, compared to 66 controls. Isovolumic placebo was administered in three studies,23,25,26 while in the remaining two studies, vitamin C was incorporated into resuscitation fluids in the intervention group.22,24 The average age was 54 years, and 72% of participants were male. Study settings were medical,25 surgical,23,26 and burn/trauma.22,26 All studies were single-center. The risk of bias summary figure is presented in Figure 2. Three of the four RCTs described some type of random sequence allocation, and these same three were also double-blinded. The Tanaka trial, despite its heading, should more accurately be considered as a quasi-randomized control trial, as the study participants therein were allocated per month of admission.22 Because blinding of outcome assessment was not specified, no trial was considered low risk. Across all domains, three studies were considered to be of unclear risk and the remaining two as high risk.

**Meta-analysis results**

**Intravenous vitamin C administration and ICU/hospital mortality**

Meta-analysis of the five included trials totaling 142 patients shows that intravenous vitamin C administration does not significantly reduce ICU and hospital mortality in critically ill patients (OR 0.76; 95% CI (0.27 to 2.16); p = 0.6) (Figure 3). Data were taken from the longest available follow-up, ranging from 6 to 28 days.23,25,26 Because study heterogeneity was moderate (I² = 50%), a random effects model was used for this analysis. A sensitivity analysis was performed by removing each study singly and reanalyzing the remaining studies; no change in the effect size was noted.

**Duration of vasopressor support**

Three studies24–26 enrolling a total of 85 patients evaluated the requirements for vasopressor support needed to maintain adequate hemodynamics. Compared to controls, the administration of intravenous vitamin C was associated with a reduced duration of vasopressor use (SMD −0.71; 95% CI (−1.16 to −0.26); p = 0.002) (Figure 4). Vasopressors administered include norepinephrine,26 vasopressin, dopamine, and phenylephrine.24 Because the data among these studies were homogeneous, a fixed effects model was used.

**Duration of mechanical ventilation**

Administration of vitamin C was associated with a reduction in the duration of mechanical ventilation in the three studies totaling 89 patients which investigated this outcome (SMD −0.5; 95% CI (−0.93 to −0.06); p = 0.03) (Figure 5). Data were reported as either time spent on ventilator support22,26 or ventilator free time.25 Again, a fixed effects model was used for this analysis.

**Fluid requirements and urine output**

Trends were noted toward both decreased fluid requirements (SMD −0.9; 95% CI (−1.86 to 0.06); p = 0.07) and urine output (SMD −0.5; 95% CI (−1.12 to 0.12); p = 0.11) in the three studies which investigated this outcome in the first 24 h of ICU admission22,24,26 (Figure 6). A random effects model was used due to high study heterogeneity. Also, in Zabet

---

**Table 1. Characteristics of included studies.**

| Study            | Design       | Setting               | Patients (n intervention/n control) | Vitamin C dose in intervention group | Overall mortality (n (%)) | Mortality follow-up |
|------------------|--------------|-----------------------|------------------------------------|--------------------------------------|--------------------------|---------------------|
| Tanaka et al.22  | Quasi-RCT    | Trauma/critical care unit | Burn > 30% TBSA (total body surface area) (19/19) | 66 mg/kg/h IV in Ringer’s lactate (RL) for 24 h | 16 (43)                  | Unspecified         |
| Ferrón-Celma et al.23 | RCT         | Surgical              | Septic patients post-abdominal surgery (10/10) | 450 mg IV × 6 days post-op | 10 (50)                  | 6 days              |
| Kahn et al.24    | Observational | Burn/trauma unit      | Burn > 20% TBSA (17/16)            | 66 mg/kg/h IV in RL for 24 h        | 7 (21)                   | 2 weeks             |
| Fowler et al.25  | RCT          | Medical ICU            | Severe sepsis (16 (8 high dose, 8 low dose)/8) | 50 mg (low dose) or 200 mg (high dose)/kg/24 h IV for 96 hours | 12 (50)                  | 28 days             |
| Zabet et al.26   | RCT          | Surgical ICU           | Surgical patients with septic shock (14/14) | 25 mg/kg IV q6 h × 72 h | 11 (39)                  | 28 days             |

RCT: randomized controlled trial.
et al. study, while there was no difference in the first 24 h, there was a trend toward increased urine output when the entire duration of the study is considered, and this would result in overall statistical significance.

**Discussion**

Although several meta-analyses have explored the effect of combination antioxidants in critical illness, our study is the first to focus exclusively on the role of vitamin C. The main results from our analysis of five studies are that vitamin C administration is not associated with decreased mortality but is associated with decreased vasopressor requirements and duration of mechanical ventilation.

Vitamin C is an essential cofactor for the production of endogenous vasopressors. Through its actions on tyrosine hydroxylase, the rate-limiting enzyme of catecholamine synthesis, and its role as a cofactor for dopamine β-hydroxylase, vitamin C is involved in the biosynthesis of norepinephrine at physiologic concentrations. Vitamin C also acts as a cofactor for peptidylglycine α-amidating monoxygenase (PAM), an enzyme that catalyzes the formation of arginine vasopressin. On the basis of these observations, Carr et al. hypothesized that “the administration of
high-dose ascorbate in conditions of hypovitaminosis C (e.g., severe sepsis and septic shock) may support the endogenous synthesis of these vasoactive compounds and thus ameliorate the need for exogenously administered vasopressors.”

It is noteworthy that, although we were able to demonstrate decreased vasopressor requirements and trends toward reduced fluid resuscitation needs and increased urine output, we did not find an overall difference in mortality. One possible reason for this discrepancy is the variance in baseline patient characteristics across the included studies. In general, the studies which did not demonstrate a numerically less mortality rate in the treatment group featured patients with relatively less severe hemodynamic derangements upon study commencement. In Tanaka et al.’s22 study, the average mean arterial pressure of enrolled patients was around 90 mm Hg, and all deaths occurred after the 96-h fluid resuscitation phase, by which time plasma vitamin C levels in the treatment group had already declined to match controls. In Kahn et al.’s study, only 4 of 17 patients in the treatment group required vasopressors compared to 9 of 16 controls. The authors note that “because one group had more than 50% more patients on vasopressors, the results would have been misleading.” In Ferrón-Celma et al.’s study, only 5 of 20 patients even required vasopressor support. Conversely, Zabet et al.26 did demonstrate decreased mortality with vitamin C administration, but the average mean arterial pressure (MAP) upon enrollment was under 70 mm Hg. Taken together, these observations support the hypothesis that
vitamin C indeed exerts a vasopressor sparing effect, but the magnitude of this effect may depend upon the initial need for vasopressor support. The benefits of supplemental vitamin C would be expected to be more pronounced in those with refractory vasopressor-dependent shock compared to patients with stable hemodynamics with little or no need for vasopressor support, and this difference in expected benefit might explain the difference in mortality among the analyzed studies. A similar line of reasoning applied to the VASSST (Vasopressin and Septic Shock) trial, where the administration of supplemental vasopressin reduced the need for norepinephrine support without affecting mortality; the authors therein speculated that the reason for this was due to the high average MAP of enrolled patients (72–73 mm Hg).90

The significance of the decreased requirements for mechanical ventilation is unknown, as is the question of whether this is actually reflective of a real improvement in pulmonary status. Across all studies, only Tanaka et al.22 demonstrated an improvement in any parameter of pulmonary function (increased PaO2/FiO2 ratio in the treatment group), but the average duration of mechanical ventilation in the treatment group was 12.1 days, far longer than the initial 24-h period of vitamin C administration. Furthermore, it is unclear whether this effect is dependent upon a decreased need for resuscitation fluids and hence a concomitant reduction in the incidence and severity of pulmonary edema or is an independent effect upon the lung parenchyma. Animal research has demonstrated that vitamin C exerts a protective effect upon the pulmonary tissues in both ischemia–reperfusion91 and lipopolysaccharide-induced models of lung injury through a variety of mechanisms, including increased alveolar fluid clearance, enhanced epithelial barrier function, and the attenuation of pro-inflammatory and pro-coagulant states accompanying sepsis.94 The same group has reported encouraging results in a recent series of case reports in the setting of acute respiratory distress syndrome (ARDS) and has recently concluded a phase II multicenter trial investigating Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI, NCT02106975).95 This study should further clarify the possible role of vitamin C in the treatment of acute lung injury and ARDS.

The optimal dose and target plasma concentration of vitamin C in the setting of critical illness are unknown. The recommended daily oral dose in healthy subjects needed to maintain normal plasma levels above 50 μmol/L is 95–110 mg/day.96 However, physiological requirements are increased during times of increased oxidative stress and metabolic turnover,12 and plasma levels have been found to be correspondingly lower in the ICU population.7 Intravenous dosing has been shown to produce higher plasma concentrations than oral administration97 due to saturable intestinal absorption,98 and 3 g/day is required to maintain plasma levels in the normal range in ICU patients.8

The five studies included in this meta-analysis featured doses as low as 450 mg/day23 to 1584 mg/kg/day,22,24 a 250-fold difference in a 70 kg subject. The difference in dosages given may result in differing effects. As previously mentioned, vitamin C is an essential cofactor for the production of endogenous vasopressors.83 It has been suggested that vitamin C is released from the adrenal cortex in response to adrenocorticotropic hormone (ACTH) to ensure that “norepinephrine synthesis [in the medulla] always proceeds at maximum velocity (Vmax).”99 Indeed, this study noted that vitamin C levels in the adrenal veins of patients with hyperaldosteronism who were administered ACTH were found to be 176 ± 71 μmol/L, over four times higher than concentrations within plasma. The authors speculated that this allows vitamin C to act locally as a paracrine mediator to stimulate norepinephrine and epinephrine synthesis. If the Carr hypothesis99 is correct, and given the suppression of corticotropin and the overall dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis during critical illness,100,101 it can be surmised that the minimum plasma concentration of vitamin C required in critical illness to support endogenous norepinephrine synthesis should be at least as great as the maximum intraadrenal concentration needed for this function in healthy controls. Analogous reasoning with hypophyseal vein concentrations can be extended for endogenous vasopressin synthesis in the setting of sepsis-related endocrine dysfunction. This level might be slightly higher given the higher pituitary concentrations of vitamin C.102

In the Fowler study, patients administered “low-dose” vitamin C at 50 mg/kg/24 h achieved an average steady-state plasma concentration of 331 μmol/L,25 above what would be expected to support endogenous norepinephrine synthesis. However, there was a further reduction in SOFA scores among patients given a higher dose of vitamin C at 200 mg/kg/24 h. Patients in this latter group achieved an average steady-state plasma concentration of 3082 μmol/L. This may suggest additional, non-hemodynamic benefits at higher, supra-physiologic doses, possibly through the antioxidant, anti-inflammatory, and microvascular actions of vitamin C, and these may be responsible for the aforementioned pulmonary benefits. Furthermore, serum levels of C-reactive protein,25 procalcitonin,25 poly(ADP-ribose) polymerase,23 and malondialdehyde22 were decreased in the intervention groups across multiple studies. Several of these markers of cellular damage have been found to correlate with organ failure beyond the cardiovascular and pulmonary systems, suggesting an overall bodily cytoprotective effect in the context of systemic inflammation.103,104

High-dose intravenous vitamin C is generally regarded as safe even in gram doses.105 No significant side effects were reported across any of these five studies. Nevertheless, caution should be exercised in patients with renal impairment.106 Although rare, oxalate nephropathy has been documented in burn patients using the same 66 mg/kg/h dose used in the Tanaka and Kahn studies.107 Patients with glucose 6-phosphate dehydrogenase deficiency and paroxysmal nocturnal hemoglobinuria should be excluded from treatment due to the risk of intravascular hemolysis.13 Although not studied in the critically ill population, potential pro-oxidant effects are
largely of academic interest only and do not appear to be of concern in noncancerous cells.\textsuperscript{108} Interestingly, one recent study in the outpatient setting suggests that intravenous vitamin C administered at gram doses may cause an acute decrease in MAP of around 7 mm Hg.\textsuperscript{109} Although this effect was limited to patients with prehypertension at baseline, vitamin C does indeed have acute vasodilatory properties;\textsuperscript{110} whether this may precipitate a paradoxical collapse in hemodynamic function in the setting of critical illness is unknown.

A major strength of this meta-analysis is that we investigated only the administration of isolated vitamin C on clinical outcomes in the critically ill, as opposed to vitamin C in combination with other agents as part of an antioxidant cocktail, the effects of which cannot be attributed properly to any particular agent. Also, a varied mix of medical, surgical, and burn patients were included, and each study contributed relatively equally in weight.

This meta-analysis has several weaknesses that should be kept in mind. First, only five studies were included due to the paucity of research on isolated vitamin C administration. Study sizes were small, with the largest study consisting of only 37 subjects, the doses used between studies was disparate, and the risk of bias was generally judged to be uncertain or high. Sample sizes for secondary outcomes were even sparser. Heterogeneity among the studies and the patient populations therein was not insignificant. In particular, mortality data had to be taken from the longest available time point in each study due to the non-uniform duration of follow-up across studies. In addition, through the inclusion of patients across many diverse settings, the gain in statistical power resulting therefrom must be weighed against the weakening association between the fixed intervention and the growing list of conditions, all under the umbrella of “critical illness,” on which the agent acts in thematic relation to. Whereas the mechanisms by which vitamin C exerts its actions have been studied mostly on animal models of sepsis and septic shock, such pathways may not persist in likewise fashion to the hypovolemic shock of burn patients; the inclusion of the latter population and the application of meta-analytic techniques thereto may result in a conclusion that dilutes or otherwise obfuscates the effects of vitamin C when applied only to sepsis. One study utilized a dose of vitamin C far below the others, and this was not adjusted for patient weight;\textsuperscript{23} however, the exclusion of this study did not affect the primary outcome of mortality. Finally, focusing on the isolated administration of vitamin C ignores any summative or synergistic benefits to be had when used in combination with other agents. Without even knowing the specific nature of vitamin C, it does seem a priori implausible that a single substance would have a substantial effect upon a parameter as global as mortality given the complex biochemical and pathophysiological milieu of critical illness. Many essential vitamin and mineral deficiencies can occur in this setting, including iron, selenium,\textsuperscript{111} magnesium,\textsuperscript{112} thiamine,\textsuperscript{113} and vitamin D,\textsuperscript{114} and repletion of several of these may be required before substantial clinical improvements are seen.

In view of these deficiencies in the primary literature, this meta-analysis should be considered as an orienting endeavor to guide future studies. Indeed, further trials are in various stages of completion in this area, exploring the role of vitamin C within the context of acute lung injury,\textsuperscript{95} severe sepsis,\textsuperscript{115,116} and septic shock.\textsuperscript{117,118} In addition, spurred by the promising results of the Marik study, trials are underway to explore the effects of vitamin C combined with thiamine and hydrocortisone.\textsuperscript{119-123} Taken together, these studies should elucidate both the role of isolated vitamin C and its synergistic effects.

Conclusion
Vitamin C deficiency is common in the context of critical illness and is associated with negative outcomes. Based on the current available evidence, the intravenous administration of vitamin C produces vasopressor sparing effects, possibly through the support of endogenous vasopressor synthesis, and reduces dependency on mechanical ventilation, possibly through the amelioration of lung injury, without affecting overall mortality. However, these conclusions should be tempered by the inherent limitations of the primary literature, particularly with respect to study heterogeneity, and forthcoming trials should further clarify the role of vitamin C in the management of the critically ill.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Michael Zhang https://orcid.org/0000-0001-7074-1021

References
1. Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 2003; 22: 18–35.
2. Sorice A, Guerriero E, Capone F, et al. Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini Rev Med Chem 2014; 14: 444–452.
3. Tyml K. Vitamin C and microvascular dysfunction in systemic inflammation. Antioxidants 2017; 6: E49.
4. Hemila H and Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013; 2013: CD000980.
5. Schleicher RL, Carroll MD, Ford ES, et al. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr 2009; 90: 1252–1263.
6. Fain O, Paries J, Jacquart B, et al. Hypovitaminosis C in hospitalized patients. Eur J Intern Med 2003; 14: 419–425.
7. Schorah CJ, Downing C, Piripitsi A, et al. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. *Am J Clin Nutr* 1996; 63: 760–765.

8. Long CL, Mauil KL, Krishnan RS, et al. Ascorbic acid dynamics in the seriously ill and injured. *J Surg Res* 2003; 109: 144–148.

9. Metnitz PG, Bartens C, Fischer M, et al. Antioxidant status in patients with acute respiratory distress syndrome. *Intensive Care Med* 1999; 25: 180–185.

10. Polidori MC, Mecocci P and Frei B. Plasma vitamin C levels are decreased and correlated with brain damage in patients with intracranial hemorrhage or head trauma. *Stroke* 2001; 32: 898–902.

11. Galley HF, Davies MJ and Webster NR. Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. *Free Radic Biol Med* 1996; 20: 139–143.

12. Berger MM. Vitamin C requirements in parenteral nutrition. *Gastroenterology* 2009; 137: S70–S78.

13. Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. *Antioxid Redox Signal* 2013; 19: 2129–2140.

14. Bell C, Carson JM, Motte NW, et al. Ascorbic acid does not affect the age-associated reduction in maximal cardiac output and oxygen consumption in healthy adults. *J Appl Physiol* 2005; 98: 845–849.

15. Fisher BJ, Seropian IM, Kraskauskas D, et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. *Crit Care Med* 2011; 39: 1454–1460.

16. Secor D, Li F, Ellis CG, et al. Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries. *Intensive Care Med* 2010; 36: 1928–1934.

17. Tyml K, Li F and Wilson JX. Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. *Crit Care Med* 2008; 36: 2355–2362.

18. McKinnon RL, Lidington D and Tyml K. Ascorbate inhibits reduced arteriolar conducted vasoconstriction in septic mouse cremaster muscle. *Microcirculation* 2007; 14: 697–707.

19. Tyml K, Li F and Wilson JX. Delayed ascorbate bolus protects against maldistribution of microvascular blood flow in septic rat skeletal muscle. *Crit Care Med* 2005; 33: 1823–1828.

20. Wu F, Wilson JX and Tyml K. Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in skeletal muscle of septic mice. *Am J Physiol Regul Integr Comp Physiol* 2003; 285: R50–R56.

21. Zhou G, Kamenos G, Pendem S, et al. Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis. *Am J Physiol Regul Integr Comp Physiol* 2012; 302: R409–R416.

22. Tanaka H, Matsuoka T, Miyagantani Y, et al. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. *Arch Surg* 2000; 135: 326–331.

23. Ferron-Celma I, Mansilla A, Hassan L, et al. Effect of vitamin C administration on neutrophil apoptosis in septic patients after abdominal surgery. *J Surg Res* 2009; 153: 224–230.

24. Kahn SA, Beers RJ and Lentz CW. Resuscitation after severe burn injury using high-dose ascorbic acid: a retrospective review. *J Burn Care Res* 2011; 32: 110–117.

25. Fowler AA III, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. *J Transl Med* 2014; 12: 32.

26. Zabet MH, Mohammadi M, Ramezani M, et al. Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock. *J Res Pharm Pract* 2016; 5: 94–100.

27. Nathens AB, Neff MJ, Jurkovich GJ, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. *Ann Surg* 2002; 236: 814–822.

28. Crimi E, Ligouri A, Condorelli M, et al. The beneficial effects of antioxidant supplementation in enterally feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. *Anesth Analg* 2004; 99: 857–863, table of contents.

29. Collier BR, Giladi A, Dossett LA, et al. Impact of high-dose antioxidants on outcomes in acutely injured patients. *JPEN J Parenter Enteral Nutr* 2008; 32: 384–388.

30. Berger MM, Segollu L, Shenkin A, et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. *Crit Care* 2008; 12: R101.

31. Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. *Chem* 2017; 151: 1229–1238.

32. Oudemans-van Straaten HM, Spoelstra-de Man AM and de Waard MC. Vitamin C revisited. *Crit Care* 2014; 18: 460.

33. Blythe R, Cook D and Graves N. Sepsicaemia: the impact on the health system and patients of delaying new treatments with uncertain evidence: a case study of the sepsis bundle. *F1000Res* 2018; 7: 500.

34. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses (PRISMA), http://prisma-statement.org (accessed 8 September 2017).

35. Hozo SP, Djulbegovic B and Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; 5: 13.

36. Higgins J and Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0, March 2011, https://handbook-5-1.cochrane.org.

37. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *Br Med J* 2011; 343: d5928.

38. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *Br Med J* 2016; 355: i4919.

39. Higgins JPT, Thompson SG, Deeks JJ, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *Br Med J* 2011; 343: d5928.

40. Ebade A, Taha WS, Saleh RH, et al. Ascorbic acid versus magnesium for the prevention of atrial fibrillation after coronary artery surgery. *Scand J Clin Lab Invest* 2001; 61: 621–629.
postoperative atrial fibrillation in on-pump coronary artery bypass graft patients. *J Cardiol* 2017; 69: 98–102.

44. Barta E, Pechan I, Cornak V, et al. Protective effect of alphatocopherol and L-ascorbic acid against the ischemic-reperfusion injury in patients during open-heart surgery. *Bratisl Lek Listy* 1991; 92: 174–183.

45. Das D, Sen C and Goswami A. Effect of vitamin C on adrenal suppression by etomidate induction in patients undergoing cardiac surgery: a randomized controlled trial. *Ann Card Anaesth* 2016; 19: 410–417.

46. Safaei N, Babaei H, Azarfarin R, et al. Comparative effect of grape seed extract (*Vitis vinifera*) and ascorbic acid in oxidative stress induced by on-pump coronary artery bypass surgery. *Ann Card Anaesth* 2017; 20: 45–51.

47. Dehghani MR, Majidi N, Rahmani A, et al. Effect of oral vitamin C on atrial fibrillation development after isolated coronary artery bypass grafting surgery: a prospective randomized clinical trial. *Cardiol J* 2014; 21: 492–499.

48. Samadikhah J, Golzari SE, Sabermarouf B, et al. Efficacy of combination therapy of statin and vitamin C in comparison with statin in the prevention of post-CABG atrial fibrillation. *Adv Pharm Bull* 2014; 4: 97–100.

49. Bjordahl PM, Helmer SD, Gosnell DJ, et al. Perioperative supplementation with ascorbic acid does not prevent atrial fibrillation in coronary artery bypass grafting patients. *Am J Surg* 2012; 204: 862–867; discussion 867.

50. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res* 2001; 89: E32–E38.

51. Colby JA, Chen WT, Baker WL, et al. Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery. *Am J Health Syst Pharm* 2011; 68: 1632–1639.

52. Esfandiari M, Badkoubeh RS, Moussavi M, et al. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. *Texas Heart Inst J* 2007; 34: 268–274.

53. Papoulidis P, Ananiadou O, Chalvatzoulis E, et al. The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience—a pilot study. *Interact Cardiovasc Thorac Surg* 2011; 12: 121–124.

54. Yamazaki E, Horikawa M and Fukushima R. Vitamin C supplementation in patients receiving peripheral parenteral nutrition after gastrointestinal surgery. *Nutrition* 2011; 27: 435–439.

55. Duffy MJ, Kane CM, Stevenson M, et al. A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair. *Intensive Care Med Exp* 2015; 3: 50.

56. Pirbudak L, Balat O, Cekmen M, et al. Effect of ascorbic acid on surgical stress response in gynecologic surgery. *Int J Clin Pract* 2004; 58: 928–931.

57. Preiser JC, Van Gossum A, Berre J, et al. Enteral feeding with a solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative stress. *Crit Care Med* 2000; 28: 3828–3832.

58. Barbosa E, Faintuch J, Machado Moreira EA, et al. Supplementation of vitamin E, vitamin C, and zinc attenuates oxidative stress in burned children: a randomized, double-blind, placebo-controlled pilot study. *J Burn Care Res* 2009; 30: 859–866.
vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA 2014; 312: 514–524.

76. Sirivardena AK, Mason JM, Balachandra S, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut 2007; 56: 1439–1444.

77. Maderazo EG, Wornick CL, Hickingbotham N, et al. A randomized trial of replacement antioxidant vitamin therapy for neutrophil locomotory dysfunction in blunt trauma. J Trauma 1991; 31: 1142–1150.

78. Porter JM, Ivatury RR, Azimuddin K, et al. Antioxidant therapy in the prevention of organ dysfunction syndrome and infectious complications after trauma: early results of a prospective randomized study. Am Surg 1999; 65: 478–483.

79. Fowler III AA, Kim C, Lepler L, et al. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. World J Crit Care Med 2017; 6: 85–90.

80. Bharara A, Grossman C, Grinnan D, et al. Intravenous vitamin C administered as adjunctive therapy for recurrent acute respiratory distress syndrome. Case Reports Crit Care 2016; 2016: 8560781.

81. Kim C, Debesa O, Nicolato P, et al. Vitamin C infusion for gastric acid aspiration-induced acute respiratory distress syndrome (ARDS). Palms Res Respir Med Open J 2017; 4: 33–37.

82. Rumelin A, Jaehde U, Kerz T, et al. Early postoperative substitution procedure of the antioxidant ascorbic acid. J Nutr Biochem 2005; 16: 104–108.

83. Patak P, Willenberg HS and Bornstein SR. Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla. Endocr Res 2004; 30: 871–875.

84. May JM, Qu Z and Meredith ME. Mechanisms of ascorbic acid stimulation of norepinephrine synthesis in neuronal cells. Biochem Biophys Res Commun 2012; 426: 148–152.

85. Seitz G, Gebhardt S, Beck JF, et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH. Neurosci Lett 1998; 244: 33–36.

86. Rahman MK, Rahman F, Rahman T, et al. Dopamine-β-hydroxylase (DBH), its cofactors and other biochemical parameters in the serum of neurological patients in Bangladesh. Int J Biomed Sci 2009; 5: 395–401.

87. UI-Hasan S, Burgess DM, Gajewiak J, et al. Characterization of the peptidylglycine α-amidating monooxygenase (PAM) from the venom ducts of neogastropods, Conus bullatus and Conus geographus. Toxicon 2013; 74: 215–224.

88. Grino M, Guillaume V, Boudouresque F, et al. Glucocorticoids regulate peptidyl-glycine alpha-amidating monooxygenase gene expression in the rat hypothalamic paraventricular nucleus. Mol Endocrinol 1990; 4: 1613–1619.

89. Carr AC, Shaw GM, Fowler AA, et al. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock? Crit Care 2015; 19: 418.

90. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877–887.

91. Baltalarli A, Ozcan V, Bir F, et al. Ascorbic acid (vitamin C) and iloprost attenuate the lung injury caused by ischemia-reperfusion of the lower extremities of rats. Ann Vasc Surg 2006; 20: 49–55.

92. Feng N-H, Chu S-J, Wang D, et al. Effects of various antioxidants on endotoxin-induced lung injury and gene expression: mRNA expressions of MnSOD, interleukin-1beta and iNOS. Chin J Physiol 2004; 47: 111–120.

93. Dwenger A, Pape HC, Bantel C, et al. Ascorbic acid reduces the endotoxin-induced lung injury in awake sheep. Eur J Clin Invest 1994; 24: 229–235.

94. Fisher BJ, Kraskauskas D, Martin EJ, et al. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol 2012; 303: L20–L32.

95. US National Library of Medicine. Vitamin C infusion for treatment in Sepsis induced acute lung injury (CITRIS-ALI). Identifier NCT02106975, 2014, https://clinicaltrials.gov/ct2/show/NCT02106975.

96. German Nutrition Society (DGE). New reference values for vitamin C intake. Ann Nutr Metab 2015; 67: 13–20.

97. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140: 533–537.

98. Burzle M and Hediger MA. Functional and physiological role of vitamin C transporters. Curr Top Membr 2012; 70: 357–375.

99. Padayatty SJ, Doppman JL, Chang R, et al. Human adrenal glands secrete vitamin C in response to adrenocorticotropic hormone. Am J Clin Nutr 2007; 86: 145–149.

100. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368: 1477–1488.

101. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock: an update. Front Endocrinol 2016; 7: 70.

102. Hornig D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann N Y Acad Sci 1975; 258: 103–118.

103. Rom S, Zuluaga-Ramirez V, Reichenbach NL, et al. PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. J Neuroinflammation 2016; 13: 254.

104. Lorente L, Martin MM, Abreu-Gonzalez P, et al. Sustained high serum malondialdehyde levels are associated with severity and mortality in septic patients. Crit Care 2013; 17: R290.

105. Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE 2010; 5: e11414.

106. Padayatty SJ, Riordan HD, Hewitt SM, et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174: 937–942.

107. Buehner M, Pamplin J, Studer L, et al. Oxalate nephropathy after continuous infusion of high-dose vitamin C as an adjunct to burn resuscitation. J Burn Care Res 2016; 37: e374–e379.

108. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102: 13604–13609.

109. Ried K, Travica N and Salih A. The acute effect of high-dose intravenous vitamin C and other nutrients on blood pressure: a cohort study. Blood Press Monit 2016; 21: 160–167.

110. Grossmann M, Dobreva D, Himmel HM, et al. Ascorbic acid-induced modulation of venous tone in humans. Hypertens 2001; 37: 949–954.

111. Ayoglu H, Sezer U, Akim M, et al. Selenium, copper, zinc, iron levels and mortality in patients with sepsis and systemic inflammatory response syndrome in Western Black Sea Region, Turkey. J Pak Med Assoc 2016; 66: 447–452.
112. Zafar MSH, Wani JI, Karim R, et al. Significance of serum magnesium levels in critically ill-patients. *Int J Appl Basic Med Res* 2014; 4: 34–37.
113. Donnino MW, Carney E, Cocchi MN, et al. Thiamine deficiency in critically ill patients with sepsis. *J Crit Care* 2010; 25: 576–581.
114. de Haan K, Groeneveld ABJ, de Geus HRH, et al. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Crit Care* 2014; 18: 660.
115. Australian New Zealand Clinical Trials Registry. Vitamin C administration in severe sepsis. Trial ID ACTRN12617001184369, https://www.anzctr.org.au/Trial /Registration/TrialReview.aspx?id=373436
116. US National Library of Medicine. High dose intravenous ascorbic acid in severe sepsis. Identifier NCT02734147, 2016, https://clinicaltrials.gov/ct2/show/NCT02734147
117. Australian New Zealand Clinical Trials Registry. Vasopressor dependent shock: intravenous vitamin C versus placebo on vasopressor use. The VALENCIA study. Trial ID ACTRN12617001392358, https://www.anzctr.org.au/Trial /Registration/TrialReview.aspx?id=373728
118. US National Library of ClinicalTrials.gov. Vitamin C and septic shock. Identifier NCT03338569, 2017, https://clinicaltrials.gov/ct2/show/NCT03338569
119. US National Library of Medicine. The vitamin C, hydrocortisone and thiamine in patients with septic shock trial (VITAMINS). Identifier NCT03333278, 2017, https://clinicaltrials.gov/ct2/show/NCT03333278
120. US National Library of Medicine. The effect of vitamin C, thiamine and hydrocortisone on clinical course and outcome in patients with severe sepsis and septic shock. Identifier NCT03335124, 2017, https://clinicaltrials.gov/ct2/show/NCT03335124
121. US National Library of Medicine. Evaluation of hydrocortisone, vitamin C and thiamine for the treatment of septic shock (HYVITS). Identifier NCT03380507, 2017, https://clinicaltrials.gov/ct2/show/NCT03380507
122. US National Library of Medicine. Ascorbic acid, corticosteroids, and thiamine in sepsis (ACTS) trial. Identifier NCT03389555, 2018, https://clinicaltrials.gov/ct2/show/NCT03389555
123. US National Library of Medicine. Metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in sepsis (ORANGES). Identifier NCT03422159, 2018, https://clinicaltrials.gov/ct2/show/NCT03422159